Hemigoxine Nativelle (Digoxin)

Hemigoxine Nativelle is indicated for the management of certain heart conditions where improved cardiac output and rhythm control are needed.

• Treatment of chronic heart failure to improve symptoms and exercise tolerance.
• Rate control in patients with atrial fibrillation or atrial flutter.
• Adjunct therapy in patients with congestive cardiomyopathy.
• Use in selected cases of supraventricular tachycardia when other agents are unsuitable.
• May be employed in palliative care to alleviate dyspnea related to cardiac dysfunction.

Side effects of digoxin can vary in frequency and severity.

Common

• Nausea or vomiting
• Diarrhea or abdominal cramps
• Fatigue or weakness
• Visual disturbances such as blurred vision or yellow‑green halos
• Dizziness or headache

Serious

• Cardiac arrhythmias (e.g., premature ventricular beats, atrioventricular block)
• Severe bradycardia
• Confusion, delirium, or hallucinations
• Hyperkalemia or electrolyte imbalance leading to toxicity
• Life‑threatening heart block

Before initiating Hemigoxine Nativelle, clinicians should evaluate several safety factors.

• Assess renal function and adjust dose in patients with impaired clearance.
• Monitor serum digoxin levels, electrolytes (especially potassium and magnesium), and thyroid function regularly.
• Use caution in patients with pre‑existing conduction disorders or bradycardia.
• Pregnancy category C: weigh potential benefits against risks; avoid use in the first trimester if possible.
• Elderly patients may be more susceptible to toxicity; start at lower doses.
• Discontinue or adjust dose before surgery or procedures that may affect fluid balance.

Digoxin interacts with a range of medications that can alter its concentration or cardiac effects.

Avoid

• Strong P‑glycoprotein inhibitors (e.g., amiodarone, quinidine, verapamil) that increase digoxin levels.
• Diuretics that cause hypokalemia or hypomagnesemia (e.g., furosemide) which predispose to toxicity.
• Certain antibiotics (e.g., erythromycin, clarithromycin) that raise serum digoxin.
• Antifungal agents like itraconazole that inhibit metabolism.

Use with caution

• Beta‑blockers and calcium channel blockers that may enhance AV‑node slowing.
• Antithyroid drugs or levothyroxine, as thyroid status influences digoxin sensitivity.
• NSAIDs that may reduce renal clearance.
• St. John’s wort, a P‑glycoprotein inducer, which can lower digoxin concentrations.